Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF: GORE CARDIOFORM Septal Occluder for Migraine
NCT04100135Terminated
- Sponsor
- W. L. Gore & Associates
- Start
- Feb 2021
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Randomised, double-blind trial in migraine (2 arms), sponsored by W. L. Gore & Associates. Primary endpoints: Reduction in Migraine Headache Days at 40 weeks and Serious Adverse Events at 30 days. Started Feb 2021; status: terminated.
02
Conditions
migraine
Beyond the preview
Go deeper on NCT04100135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100135.